Investors in GRAIL, Inc. Invited to Join Class Action Regarding Alleged Securities Fraud

Class Action Lawsuit Filed Against GRAIL, Inc.

On August 4, 2026, Hagens Berman Sobol Shapiro LLP announced the initiation of a securities fraud class action lawsuit aimed at GRAIL, Inc. (NASDAQ: GRAL). This alert is particularly relevant for investors who have experienced substantial financial losses while holding GRAIL stock within the specified timeframe of May 13, 2025, to February 19, 2026. The firm is urgently reaching out to affected investors, urging them to file claims ahead of the approaching deadline of August 4, 2026.

Background of the Case

The lawsuit centers around certain claims made by GRAIL regarding its NHS-Galleri cancer screening trial. Allegations suggest that GRAIL and some of its senior executives misrepresented the trial's clinical design and efficacy. Specifically, it is contended that GRAIL falsely assured investors about the structure of the study, characterizing it as optimally configured with a follow-up period designed to demonstrate significant effectiveness in reducing late-stage cancer diagnoses.

Central to the lawsuit is the accusation that GRAIL selectively highlighted initial positive results while failing to disclose critical data that could indicate the study might not achieve its intended primary endpoint. Investors allege that the company hid information suggesting that the three-year follow-up period would not suffice for comprehensive and affirming results.

Key Allegations and Market Reaction

The issues escalated dramatically on February 19, 2026, when GRAIL unveiled the results from the NHS-Galleri trial, which indicated a failure to meet its primary endpoint. Following this announcement, GRAIL admitted the need for a longer follow-up than originally proposed, leading to an astonishing 50.55% decline in the value of its stock. The share price plummeted from $101.53 to $50.21 within a single trading day, wiping out over $2.2 billion in market capitalization. This severe drop highlighted the devastating impact that the disclosures had on investor confidence and trust.

Investigative Focus

Hagens Berman is now actively investigating the timeline concerning when GRAIL's management became aware that their stated follow-up period was misaligned with the actual requirements for the trial. Partner Reed Kathrein, who is overseeing the investigation, stated that they have a keen interest in uncovering when management knew about these discrepancies and how they communicated them to stakeholders.

Next Steps for Affected Investors

For individuals who acquired GRAIL common stock during the specified class period and have suffered financial damages, the opportunity exists to seek the position of lead plaintiff in this class action lawsuit. Investors should promptly reach out to Hagens Berman to understand their legal options and participate before the deadline.

Moreover, for whistleblowers possessing knowledge that could aid in the investigation, there are rewards available under the SEC's Whistleblower Program, which can provide up to 30% of any successful recovery.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a distinguished legal firm representing plaintiffs in complex litigation, specializing in corporate accountability. The firm has a successful track record, having secured over $2.9 billion for clients impacted by corporate malfeasance. For further information about the allegations against GRAIL and the class action lawsuit, or to inquire about legal assistance, investors are encouraged to visit Hagens Berman's official website. Follow the firm for ongoing updates related to this case and other news.